BioCryst Pharmaceuticals, Inc. $BCRX Stock Position Reduced by Royal Bank of Canada

Posted by Geri Gentry on Aug 30th, 2026

Royal Bank of Canada decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 88.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 18,115 shares of the biotechnology company’s stock after selling 143,341 shares during the period. Royal Bank of Canada’s holdings in BioCryst Pharmaceuticals were worth $173,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after purchasing an additional 482,494 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of BioCryst Pharmaceuticals by 21.4% during the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after purchasing an additional 448,436 shares during the period. Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 17.1% in the 1st quarter. Rice Hall James & Associates LLC now owns 2,230,105 shares of the biotechnology company’s stock worth $21,231,000 after buying an additional 325,959 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $21,771,000. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 524.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 163,266 shares of the biotechnology company’s stock valued at $1,554,000 after buying an additional 137,133 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BCRX shares. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Citizens Jmp upped their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Needham & Company LLC dropped their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Cantor Fitzgerald increased their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.60.

Read Our Latest Stock Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $9.82 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The business’s fifty day moving average price is $9.71 and its two-hundred day moving average price is $9.05. The company has a market capitalization of $2.51 billion, a P/E ratio of -6.55 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period last year, the company earned $0.15 earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.